Saniona AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0005794617
SEK
15.56
-0.52 (-3.23%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Net Sales of 4324.19%, the company declared Outstanding results in Sep 25

  • OPERATING CASH FLOW(Y) Highest at SEK 651.96 MM
  • ROCE(HY) Highest at 171.55%
  • DEBTORS TURNOVER RATIO(HY) Highest at 72.07 times
2

With ROE of 60.17%, it has a attractive valuation with a 5.53 Price to Book Value

3

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 2,261 Million (Small Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

83.18%

stock-summary
Price to Book

3.28

Revenue and Profits:
Net Sales:
411 Million
(Quarterly Results - Sep 2025)
Net Profit:
330 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.47%
0%
-24.47%
6 Months
26.71%
0%
26.71%
1 Year
177.86%
0%
177.86%
2 Years
750.27%
0%
750.27%
3 Years
194.71%
0%
194.71%
4 Years
258.48%
0%
258.48%
5 Years
-21.75%
0%
-21.75%

Saniona AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
176.36%
EBIT Growth (5y)
46.99%
EBIT to Interest (avg)
-8.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.71
Tax Ratio
7.99%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
17.87%

Valuation key factors

Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
5.53
EV to EBIT
7.30
EV to EBITDA
7.07
EV to Capital Employed
30.62
EV to Sales
4.91
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
419.47%
ROE (Latest)
60.17%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 4,316.13% vs -5.10% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 1,584.68% vs -216.84% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "410.70",
          "val2": "9.30",
          "chgp": "4,316.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "362.40",
          "val2": "-22.90",
          "chgp": "1,682.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "1.00",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "329.60",
          "val2": "-22.20",
          "chgp": "1,584.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "878.10%",
          "val2": "-2,635.00%",
          "chgp": "351.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,892.26% vs 9.80% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 296.97% vs 54.73% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "334.70",
          "val2": "16.80",
          "chgp": "1,892.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "246.80",
          "val2": "-69.70",
          "chgp": "454.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "38.90",
          "val2": "24.90",
          "chgp": "56.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "188.70",
          "val2": "-95.80",
          "chgp": "296.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "714.50%",
          "val2": "-4,711.80%",
          "chgp": "542.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
410.70
9.30
4,316.13%
Operating Profit (PBDIT) excl Other Income
362.40
-22.90
1,682.53%
Interest
3.00
1.00
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
329.60
-22.20
1,584.68%
Operating Profit Margin (Excl OI)
878.10%
-2,635.00%
351.31%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 4,316.13% vs -5.10% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 1,584.68% vs -216.84% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
334.70
16.80
1,892.26%
Operating Profit (PBDIT) excl Other Income
246.80
-69.70
454.09%
Interest
38.90
24.90
56.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
188.70
-95.80
296.97%
Operating Profit Margin (Excl OI)
714.50%
-4,711.80%
542.63%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1,892.26% vs 9.80% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 296.97% vs 54.73% in Dec 2023

stock-summaryCompany CV
About Saniona AB stock-summary
stock-summary
Saniona AB
Pharmaceuticals & Biotechnology
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Company Coordinates stock-summary
Company Details
Baltorpvej 154 , BALLERUP None : 2750
Registrar Details